AXSM – Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSM

$111.91

Name : Axsome Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $5,510,045,696.00

EPSttm : -5.77

Axsome Therapeutics, Inc.

$111.91

1.13%

$1.25

Float Short %

9.61

Margin Of Safety %

Put/Call OI Ratio

0.66

EPS Next Q Diff

0.36

EPS Last/This Y

2.28

EPS This/Next Y

5.26

Price

111.86

Target Price

178.1

Analyst Recom

1.05

Performance Q

-8.4

Relative Volume

Beta

0.47

Ticker: AXSM

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	AXSM	108.76	0.81	0.47	27373
2025-05-09	AXSM	107.66	0.81	0.33	27637
2025-05-12	AXSM	110.24	0.81	0.13	27942
2025-05-13	AXSM	105.54	0.80	0.22	28159
2025-05-14	AXSM	103.92	0.79	0.74	28227
2025-05-15	AXSM	106.58	0.78	0.31	28325
2025-05-16	AXSM	107.47	0.79	0.25	28127
2025-05-19	AXSM	108.31	0.72	0.22	22260
2025-05-20	AXSM	108.28	0.72	0.53	22484
2025-05-21	AXSM	105.75	0.71	0.30	22609
2025-05-22	AXSM	104.18	0.71	0.21	22640
2025-05-23	AXSM	104.99	0.71	5.30	22657
2025-05-27	AXSM	104.01	0.74	0.14	23070
2025-05-28	AXSM	102.94	0.74	0.16	23103
2025-05-29	AXSM	104.64	0.75	0.13	22989
2025-05-30	AXSM	105.16	0.75	0.04	22958
2025-06-02	AXSM	107.59	0.74	0.09	23247
2025-06-03	AXSM	109.47	0.71	0.21	23870
2025-06-04	AXSM	108.18	0.68	0.29	24705
2025-06-05	AXSM	110.65	0.68	0.04	24725
2025-06-06	AXSM	111.92	0.66	0.22	25200
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	AXSM	108.86	34.4	164.8	-3.85
2025-05-09	AXSM	107.75	36.1	164.0	-3.71
2025-05-12	AXSM	110.16	36.1	160.4	-3.71
2025-05-13	AXSM	105.60	35.5	167.4	-3.82
2025-05-14	AXSM	103.71	36.1	164.9	-3.71
2025-05-15	AXSM	107.33	35.2	159.0	-3.71
2025-05-16	AXSM	107.49	35.2	162.6	-3.85
2025-05-19	AXSM	108.30	35.0	99.1	-3.85
2025-05-20	AXSM	108.38	35.0	100.2	-3.74
2025-05-21	AXSM	105.79	35.0	104.4	-3.74
2025-05-22	AXSM	104.24	35.0	102.8	-3.74
2025-05-23	AXSM	105.04	35.0	99.2	-3.74
2025-05-27	AXSM	103.98	35.0	102.1	-3.74
2025-05-28	AXSM	102.98	35.0	102.0	-3.74
2025-05-29	AXSM	104.52	35.0	97.8	-3.74
2025-05-30	AXSM	105.16	35.0	99.5	-3.74
2025-06-02	AXSM	107.63	35.0	96.3	-3.74
2025-06-03	AXSM	110.11	35.0	96.4	-3.74
2025-06-04	AXSM	108.18	35.0	103.4	-3.74
2025-06-05	AXSM	110.66	35.3	96.3	-3.71
2025-06-06	AXSM	111.86	36.0	98.4	-3.71
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	AXSM	-0.17	-1.41	10.93
2025-05-09	AXSM	-0.17	-1.41	10.93
2025-05-12	AXSM	-0.17	-1.05	10.37
2025-05-13	AXSM	-0.17	-1.05	10.37
2025-05-14	AXSM	-0.17	-1.05	10.37
2025-05-15	AXSM	-0.17	-1.05	10.37
2025-05-16	AXSM	-0.17	-1.05	10.37
2025-05-19	AXSM	-0.17	1.42	10.37
2025-05-20	AXSM	-0.17	1.42	10.37
2025-05-21	AXSM	-0.20	1.42	10.37
2025-05-22	AXSM	-0.20	1.42	10.37
2025-05-23	AXSM	-0.20	1.42	10.37
2025-05-27	AXSM	-0.20	-0.86	10.37
2025-05-28	AXSM	-0.20	-0.86	9.61
2025-05-29	AXSM	-0.66	-0.86	9.61
2025-05-30	AXSM	-0.75	-0.86	9.61
2025-06-02	AXSM	-0.75	0.22	9.61
2025-06-03	AXSM	-0.75	0.22	9.61
2025-06-04	AXSM	-0.75	0.22	9.61
2025-06-05	AXSM	-0.75	0.22	9.61
2025-06-06	AXSM	-0.75	0.22	9.61
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.22

Avg. EPS Est. Current Quarter

-1.07

Avg. EPS Est. Next Quarter

-0.86

Insider Transactions

-0.75

Institutional Transactions

0.22

Beta

0.47

Average Sales Estimate Current Quarter

140

Average Sales Estimate Next Quarter

162

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

19.6

Max Drawdown 5-Year %

-77

Target Price

178.1

P/E

Forward P/E

65.34

PEG

P/S

12.75

P/B

103.52

P/Free Cash Flow

EPS

-5.77

Average EPS Est. Cur. Y

-3.71

EPS Next Y. (Est.)

1.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-64.39

Relative Volume

Return on Equity vs Sector %

-547.1

Return on Equity vs Industry %

-529.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.3

EBIT Estimation

98.4

Axsome Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 712

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

stock quote shares AXSM – Axsome Therapeutics, Inc. Stock Price stock today

news today AXSM – Axsome Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AXSM – Axsome Therapeutics, Inc. yahoo finance google finance

stock history AXSM – Axsome Therapeutics, Inc. invest stock market

stock prices AXSM premarket after hours

ticker AXSM fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

AXSM – Axsome Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AXSM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y